Skip to main content
. 2017 Jul 25;19(9):661–671. doi: 10.1016/j.neo.2017.06.001

Figure 4.

Figure 4

Rituximab cotreatment increases the internalization of the CD37-targeting moiety of IMGN529. (A) U-2932 cells (left panel) and SU-DHL-4 cells (right panel) cells were incubated with AF488-labeled K7153A in the presence or absence of the indicated control or anti-CD20 antibodies at 37°C for 30 minutes, 2 hours, and 6 hours. The percent internalization was determined by flow cytometry (*P < .0001, unpaired t test). (B) The internalization of AF488-labeled rituximab was determined alone or in the presence of K7153A or anti-CD19 antibodies in U-2932 (left panel) and SU-DHL-4 cells (right panel) cells.